恩帕吉菲
医学
胰岛素抵抗
糖尿病
耐火材料(行星科学)
打开标签
临床试验
2型糖尿病
内科学
重症监护医学
外科
内分泌学
天体生物学
物理
作者
Yushi Hirota,Yasumasa Kakei,Junta Imai,Hideki Katagiri,Ken Ebihara,Jun Wada,Junichi Suzuki,Tatsuhiko Urakami,Takashi Omori,Wataru Ogawa
摘要
Insulin resistance syndrome and lipoatrophic diabetes are rare conditions characterized by the development of treatment-refractory diabetes with severe insulin resistance. We recently conducted a 24 week, multicenter, single-arm trial (EMPIRE-01) that demonstrated a certain level of effectiveness and safety of empagliflozin for these conditions. To evaluate treatment safety over a longer period, we have now performed an additional 28 week trial (EMPIRE-02) that followed on from EMPIRE-01.
科研通智能强力驱动
Strongly Powered by AbleSci AI